IQV Stock Recent News

IQVIA Holdings, Inc. (IQV) Q4 2023 Earnings Call Transcript

IQVIA Holdings' (IQV) revenues increase year over year in fourth-quarter 2023.

IQVIA Holdings (IQV) came out with quarterly earnings of $2.84 per share, beating the Zacks Consensus Estimate of $2.82 per share. This compares to earnings of $2.78 per share a year ago.

IQVIA's (IQV) revenues are likely to increase year over year on the back of improving segmental performance.

Evaluate the expected performance of IQVIA (IQV) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Idexx Laboratories (IDXX). But which of these two companies is the best option for those looking for undervalued stocks?

IQVIA (IQV) benefits from revenue growth and disciplined cost management.

IQVIA (IQV) aims at market expansion through innovation and service improvements.

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?

IQVIA is a global provider of contract research services and data analytics for the healthcare industry. The company helps clients drive healthcare forward by providing insights and solutions to improve. The Net Debt/EBITDA ratio is 4.6x, moreover, 55% of its debt is at a floating rate, which is very worrying in an environment with high rates. Although the company doesn't seem particularly expensive at its current valuation, I would demand a greater margin of safety until debt concerns are resolved.